TransCode Therapeutics, Inc. received multiple deficiency letters from Nasdaq regarding non-compliance with minimum bid price and stockholders equity requirements, and is appealing the delisting decision with a hearing scheduled for October 1, 2024.
AI Assistant
TRANSCODE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.